India Moves Closer to Indigenous Single-Dose Dengue Vaccine
India is moving closer to having its own domestically developed dengue vaccine, with the DengiAll candidate now in the final stages of its Phase III clinical trial.

Developed by Panacea Biotec in collaboration with ICMR, DengiAll is designed as a single-dose, tetravalent vaccine targeting all four major dengue virus serotypes. More than 13,000 volunteers across 20 centres are being followed as part of the randomized clinical study.
ICMR Director General Rajiv Bahl said researchers have completed almost a year of follow-up and are hopeful of unblinding the trial results by the end of 2027. The final results will be important for determining the vaccine’s efficacy and safety before any regulatory approval can be considered.
Dengue protection is particularly challenging because the virus has four major serotypes. DengiAll has been designed to generate an immune response against all four, potentially allowing protection through a single dose if the Phase III study demonstrates sufficient efficacy and safety.
ICMR’s official documentation confirms that the Phase III study is a multicentre, randomized, double-blind and placebo-controlled trial evaluating the vaccine’s efficacy, immunogenicity and safety in healthy Indian adults.
The development comes as India has already approved its first dengue vaccine, Qdenga, manufactured by Takeda. DengiAll remains an investigational candidate and cannot be assumed to be approved or available for public use until the required clinical and regulatory processes are completed.
If the ongoing trial produces favourable results and subsequent regulatory review is successful, DengiAll could become an important addition to India’s dengue-prevention programme.